| Dostarlimab studied in …STUDIED_INderived89 of 89show fewer |
|---|
| → studied in | NCT04584255Phase 2 · active not recruiting Niraparib + Dostarlimab In BRCA Mutated Breast Cancer · 89 trials list this drug (59 active) | — | — | Breast Neoplasm,Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06062420Phase 2 · active not recruiting A Platform Study of Novel Immunotherapy Combinations as First-Line Treatment in Participants With PD-L1 Positive Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck- GALAXIES H&N-202 · 89 trials list this drug (59 active) | — | — | Head and Neck Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04387084Phase 1 · active not recruiting Short-term Fasting Prior to PD-1/PD-L1 Inhibitor Therapy for of Advanced or Metastatic Skin Malignancy · 89 trials list this drug (59 active) | — | — | Malignant Skin Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04493060Phase 2 · completed Niraparib and Dostarlimab for the Treatment of Germline or Somatic BRCA1/2 and PALB2 Mutated Metastatic Pancreatic Cancer · 89 trials list this drug (59 active) | — | — | Malignant Pancreatic Neoplasm,Pancreatic Ductal Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06405230Phase 1/Phase 2 · terminated Evaluation of Programmed Death Ligand 1 (PDL1) Response to Treatment in Extracellular Vesicles (EVs), Patient-derived Organoid (PDOs)s and Immune-marker Positron Emission Tomography (PET) Scanning in Non-small Cell Lung Cancer (NSCLC) · 89 trials list this drug (59 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07684599Phase 3 · not yet recruiting A Study to Investigate Mocertatug Rezetecan as Maintenance Treatment for Participants With MMRp Endometrial Cancer (BEHOLD-Endometrial02) · 89 trials list this drug (59 active) | — | — | Endometrial Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02715284Phase 1 · active not recruiting Study of TSR-042, an Anti-programmed Cell Death-1 Receptor (PD-1) Monoclonal Antibody, in Participants With Advanced Solid Tumors · 89 trials list this drug (59 active) | — | — | Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04673448Phase 1 · active not recruiting Niraparib and TSR-042 for the Treatment of BRCA-Mutated Unresectable or Metastatic Breast, Pancreas, Ovary, Fallopian Tube, or Primary Peritoneal Cancer · 89 trials list this drug (59 active) | — | — | Malignant Solid Neoplasm,Breast Carcinoma,Malignant Pancreatic Neoplasm+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07336147Phase 2 · recruiting Dostarlimab, Cisplatin and Etoposide in Combination With Radiotherapy in Sandwich Sequence for Small Cell Neuroendocrine Cervical Carcinoma · 89 trials list this drug (59 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03843359Phase 1 · terminated A First Time in Human (FTIH) Study of GSK3745417 Administered to Participants With Advanced Solid Tumors · 89 trials list this drug (59 active) | — | — | Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07740720Phase 3 · not yet recruiting A Study of the Duration of Dostarlimab in Untreated Mismatch Repair Deficient (dMMR)/ Microsatellite Instability-high (MSI-H) Locally Advanced Rectal Cancer · 89 trials list this drug (59 active) | — | — | Rectal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06472076Phase 3 · active not recruiting A Study of Belrestotug Plus Dostarlimab Compared With Placebo Plus Pembrolizumab in Previously Untreated Participants With Programmed Death Ligand 1 (PD-L1) High Non-small-cell Lung Cancer (NSCLC) · 89 trials list this drug (59 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04774419Phase 2 · recruiting Radiation and TSR-042 (Dostarlimab) in People With Endometrial Cancer After They Receive Surgery · 89 trials list this drug (59 active) | — | — | Malignant Endometrial Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06796907Phase 1/Phase 2 · recruiting A Study of Mocertatug Rezetecan in Combination With Anti-cancer Therapies for Advanced Solid Tumors (BEHOLD-2) · 89 trials list this drug (59 active) | — | — | Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04655976Phase 2/Phase 3 · active not recruiting Efficacy Comparison of Cobolimab + Dostarlimab + Docetaxel to Dostarlimab + Docetaxel to Docetaxel Alone in Participants With Advanced Non-small Cell Lung Cancer Who Have Progressed on Prior Anti-PD-(L)1 Therapy and Chemotherapy · 89 trials list this drug (59 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04926324Phase 1 · terminated A Safety Study Adding Niraparib and Dostarlimab to Radiation Therapy for Rectal Cancers · 89 trials list this drug (59 active) | — | — | Rectal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05277051Phase 1 · active not recruiting First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumors · 89 trials list this drug (59 active) | — | — | Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03016338Phase 2 · active not recruiting Study of Niraparib and TSR-042 in Recurrent Endometrial Cancer · 89 trials list this drug (59 active) | — | — | Malignant Endometrial Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06065462Phase 1/Phase 2 · recruiting Safety and Efficacy of Targeting PP2A in Ovarian Clear Cell Carcinoma Using Dostarlimab and LB-100 · 89 trials list this drug (59 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03833479Phase 2 · active not recruiting TSR-042 as Maintenance Therapy for Patients With High-risk Locally Advanced Cervical Cancer After Chemo-radiation · 89 trials list this drug (59 active) | — | — | Malignant Neoplasm,Malignant Cervical Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04837209Phase 2 · active not recruiting Radiation, Immunotherapy and PARP Inhibitor in Triple Negative Breast Cancer · 89 trials list this drug (59 active) | — | — | Malignant Breast Neoplasm,Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07652515Phase 4 · not yet recruiting A Study to Evaluate the Safety of Dostarlimab in Adult Participants in India With Primary Advanced or Recurrent Endometrial Cancer · 89 trials list this drug (59 active) | — | — | Endometrial Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05565378Phase 2 · active not recruiting A Platform Study of Novel Immunotherapy Combinations in Participants With Previously Untreated, Advanced/Metastatic Non-Small-Cell Lung Cancer · 89 trials list this drug (59 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05239546Phase 2 · recruiting Single Arm Study of Neoadjuvant Dostarlimab in Stage II and III Deficient Mismatch Repair Colon Cancers · 89 trials list this drug (59 active) | — | — | Malignant Colon Neoplasm,dMMR Colorectal Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05819892Phase 1 · recruiting Phase I Trial Testing the Safety and Tolerability of Chemoradiation Followed by Chemotherapy + Dostarlimab for Stage IIIC, Node Positive, Endometrial Cancer · 89 trials list this drug (59 active) | — | — | Malignant Endometrial Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05784012Phase 1/Phase 2 · active not recruiting Two-cohort Study of Niraparib and Dostarlimab Plus (Chemo)RadIotherapy in Locally-Advanced Head and Neck Squamous Cell Carcinoma · 89 trials list this drug (59 active) | — | — | Head and Neck Squamous Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05723562Phase 2 · active not recruiting A Study of Dostarlimab in Untreated dMMR/MSI-H Locally Advanced Rectal Cancer · 89 trials list this drug (59 active) | — | — | Rectal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06256588Phase 3 · recruiting A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma · 89 trials list this drug (59 active) | — | — | Head and Neck Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06551142Phase 1 · recruiting A Study of GSK5764227 in Participants With Advanced Solid Tumors (EMBOLD) · 89 trials list this drug (59 active) | — | — | Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06567782Phase 2 · recruiting A Study of Neoadjuvant Dostarlimab Plus Capecitabine Plus Oxaliplatin (CAPEOX) Vs CAPEOX With Previously Untreated T4N0 or Stage III Mismatch Repair Proficient (MMRp)/Microsatellite Stable (MSS) Colon Cancer · 89 trials list this drug (59 active) | — | — | Colon Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04313504Phase 2 · completed Study Evaluating the Efficacy of Niraparib and Dostarlimab (TSR-042) in Recurrent/Metastatic HNSCC · 89 trials list this drug (59 active) | — | — | Malignant Head and Neck Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04126200Phase 1/Phase 2 · active not recruiting Platform Study of Belantamab Mafodotin as Monotherapy and in Combination With Anti-cancer Treatments in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) · 89 trials list this drug (59 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06023862Phase 2 · recruiting A Three-arm Randomized Phase II Study of Dostarlimab Alone or With Bevacizumab Versus Nonplatinum Chemotherapy in Recurrent Gynecological Clear Cell Carcinoma: DOVE (APGOT-OV7/ ENGOT-ov80 Study) · 89 trials list this drug (59 active) | — | — | Ovarian Neoplasm,Clear Cell Adenocarcinoma,Vaginal Neoplasm+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07408063Phase 2 · recruiting A Comprehensive Multiomic Biomarker Evaluation Across Two Single-arm Cohorts to Elucidate Mechanisms of Response and Resistance in Recurrent/Metastatic (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC) · 89 trials list this drug (59 active) | — | — | Head and Neck Squamous Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04701307Phase 2 · active not recruiting Niraparib and Dostarlimab for the Treatment of Small Cell Lung Cancer and Other High-Grade Neuroendocrine Carcinomas · 89 trials list this drug (59 active) | — | — | Malignant Lung Neoplasm,Neuroendocrine Carcinoma,Lung Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05870761Phase 2 · active not recruiting Combination Niraparib and Dostarlimab Therapy for Recurrent or Persistent Uterine Serous Carcinoma · 89 trials list this drug (59 active) | — | — | Endometrial Serous Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06830239Phase 2 · recruiting Phase II Study of Neoadjuvant Dostarlimab in Patients With Untreated T3-4N0-2 or Stage III pMMR/MSS Resectable Colon Cancer · 89 trials list this drug (59 active) | — | — | Malignant Colon Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04068753Phase 2 · active not recruiting Niraparib in Combination With Dostarlimab in Patients With Recurrent or Progressive Cervix Cancer · 89 trials list this drug (59 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05700721Phase 2 · recruiting Phase II Trial of the PARP Inhibitor Niraparib and PD-1 Inhibitor Dostarlimab in Patients With Advanced Cancers With Active Progressing Brain Metastases (STARLET) · 89 trials list this drug (59 active) | — | — | Brain Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07381777Phase 2 · not yet recruiting XELOX Plus DoSTARlimab Versus XELOX Alone as Consolidation Treatment After Standard Chemoradiation in pMMR/MSS or MSI-Low Locally Advanced Rectal Cancer (LARC) Patients · 89 trials list this drug (59 active) | — | — | Malignant Rectal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05855200Phase 3 · recruiting Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer · 89 trials list this drug (59 active) | — | — | Colon Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04544995Phase 1 · terminated Dose Escalation and Cohort Expansion Study of Niraparib and Dostarlimab in Paediatric Participants With Solid Tumors (SCOOP) · 89 trials list this drug (59 active) | — | — | Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06879717Phase 1/Phase 2 · active not recruiting A Study of Roginolisib (IOA-244) in Combination With Dostarlimab With or Without Docetaxel in Metastatic Non Small-cell Lung Cancer (NSCLC) Patients · 89 trials list this drug (59 active) | — | — | Lung Non-Squamous Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06238635Phase 2 · active not recruiting Dostarlimab and Cobolimab in Advanced Cervical Cancer · 89 trials list this drug (59 active) | — | — | Cervical Carcinoma,Malignant Cervical Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03955978Phase 1 · active not recruiting TSR-042 in Addition to Standard of Care Definitive Radiation for Inoperable Endometrial Cancer · 89 trials list this drug (59 active) | — | — | Endometrial Neoplasm,Malignant Endometrial Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03602859Phase 3 · active not recruiting A Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care (SOC) Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer · 89 trials list this drug (59 active) | — | — | Ovarian Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07108270Phase 2 · recruiting A Study of Dostarlimab in Combination With Carboplatin-paclitaxel in Chinese Participants With Primary Advanced or Recurrent Endometrial Cancer (EC) · 89 trials list this drug (59 active) | — | — | Endometrial Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07269249recruiting Real-world Efficacy and Safety of Neoadjuvant Dostarlimab in Patients With dMMR/MSI-H Locally Advanced Rectal Cancer · 89 trials list this drug (59 active) | — | — | Malignant Rectal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05201547Phase 3 · active not recruiting Endometrial Cancer Patientes MMR Deficient Comparing Chemotherapy vs Dostarlimab in First Line · 89 trials list this drug (59 active) | — | — | Malignant Endometrial Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05526989Phase 2 · recruiting Study of the Combination Dostarlimab With Niraparib In Patients With Penile Carcinoma · 89 trials list this drug (59 active) | — | — | Penile Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06333314Phase 2 · recruiting Dostarlimab for Locally Advanced or Metastatic Cancer (Non-colorectal/Non-endometrial) With Tumor dMMR/MSI · 89 trials list this drug (59 active) | — | — | Sarcoma,Neuroendocrine Carcinoma,Soft Tissue Sarcoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04779151Phase 2 · terminated Basket Trial Exploring the Efficacy and Safety of the Combination of Niraparib and Dostarlimab · 89 trials list this drug (59 active) | — | — | Malignant Head and Neck Neoplasm,Malignant Biliary Tract Neoplasm,Urothelial Carcinoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03307785Phase 1 · completed Study of Niraparib, TSR-022, Bevacizumab, and Platinum-Based Doublet Chemotherapy in Combination With TSR-042 · 89 trials list this drug (59 active) | — | — | Neoplasm,Malignant Neoplasm,Solid Neoplasm+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06640049Phase 2 · active not recruiting A Study of Dostarlimab in Participants With Untreated Locally Advanced Rectal Cancer in China · 89 trials list this drug (59 active) | — | — | Rectal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05980416Phase 1 · terminated Study of EO-3021 in Adult Patients With Solid Tumors Likely to Express CLDN18.2 · 89 trials list this drug (59 active) | — | — | Neoplasm,Neoplasm by Site,Digestive System Neoplasm+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06521567Phase 1/Phase 2 · active not recruiting A Study of Cobolimab Plus Dostarlimab in Pediatric and Young Adult Participants With Cancer · 89 trials list this drug (59 active) | — | — | Hepatoblastoma,Melanoma,Glioblastoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02817633Phase 1 · active not recruiting A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER) · 89 trials list this drug (59 active) | — | — | Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04446351Phase 1 · active not recruiting Study of the Safety and Effectiveness of GSK6097608 in Participants With Advanced Solid Tumors · 89 trials list this drug (59 active) | — | — | Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04139902Phase 2 · active not recruiting Neoadjuvant PD-1 Inhibitor Dostarlimab (TSR-042) vs. Combination of Tim-3 Inhibitor Cobolimab (TSR-022) and PD-1 Inhibitor Dostarlimab (TSR-042) in Melanoma · 89 trials list this drug (59 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03981796Phase 3 · active not recruiting A Study to Evaluate Dostarlimab Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Participants With Recurrent or Primary Advanced Endometrial Cancer · 89 trials list this drug (59 active) | — | — | Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07115927Phase 2 · not yet recruiting pReOperative Dostarlimab and Novel Therapies in EndOmetrial Cancer · 89 trials list this drug (59 active) | — | — | Malignant Endometrial Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04409002Phase 2 · completed Niraparib + Dostarlimab + RT in Pancreatic Cancer · 89 trials list this drug (59 active) | — | — | Malignant Pancreatic Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04581824Phase 2 · terminated Efficacy Comparison of Dostarlimab Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Participants With Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) · 89 trials list this drug (59 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06317311Phase 2 · active not recruiting A Study of Dostarlimab in Combination With Carboplatin-paclitaxel in Japanese Participants With Primary Advanced or Recurrent Endometrial Cancer · 89 trials list this drug (59 active) | — | — | Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03574779Phase 2 · completed A Study to Evaluate the Efficacy and Safety of Novel Treatment Combinations in Participants With Ovarian Cancer · 89 trials list this drug (59 active) | — | — | Ovarian Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06897527Phase 4 · not yet recruiting A Study to Evaluate the Safety of Dostarlimab in Adult Participants in India With Recurrent or Advanced Endometrial Cancer (EC) · 89 trials list this drug (59 active) | — | — | Endometrial Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06926673Phase 2 · completed Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC) - Sub-study 3 · 89 trials list this drug (59 active) | — | — | Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03739710Phase 2 · completed Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC) · 89 trials list this drug (59 active) | — | — | Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07013851Phase 2 · not yet recruiting Clinical Trial to Assess the Efficacy of Dostarlimab as Neoadjuvant Therapy in Patients With MMRd/MSI-H Stage II-III Endometrial Cancer · 89 trials list this drug (59 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05126342Phase 2 · withdrawn Study to Estimate Efficacy of Combining Dostarlimab and Niraparib in Relapsed EOC After Treatment With PARPi · 89 trials list this drug (59 active) | — | — | Malignant Fallopian Tube Neoplasm,Malignant Ovarian Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06385548Phase 1/Phase 2 · withdrawn Efficacy and Safety Study of Lurbinectedin and Dostarlimab in Cancer Patients: Protocol VHIO21001 - LiDer · 89 trials list this drug (59 active) | — | — | Malignant Endometrial Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06757244Phase 2 · recruiting DOVIPA, a Study Evaluating Efficacy and Safety of DOstarlimab and VItamin D3 With mFOLFIRINOX in PAncreatic Cancer · 89 trials list this drug (59 active) | — | — | Pancreatic Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06655818Phase 1/Phase 2 · terminated Sub-study of Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination With Dostarlimab (GSK4057190) in Participants With RRMM · 89 trials list this drug (59 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06762405Phase 3 · recruiting PRODIGE 90 - (FFCD 2204) Neoadjuvant Dostarlimab with Short Course Radiotherapy in a Watch-and-wait Strategy for Microsatellite Unstable or Mismatch Repair-deficient Locally Advanced Rectal Cancer Patients · 89 trials list this drug (59 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06365970Phase 2 · withdrawn Niraparib and Dostarlimab for Patients With MMR-D/MSI-H Colorectal Cancers · 89 trials list this drug (59 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02723955Phase 1 · completed Dose Escalation and Expansion Study of GSK3359609 in Participants With Selected Advanced Solid Tumors (INDUCE-1) · 89 trials list this drug (59 active) | — | — | Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06278857Phase 2 · recruiting SATELLITE Study (feaSibility sAfeTy Efficacy dostarLimab earLy-stage defIcient endomeTrial cancEr) · 89 trials list this drug (59 active) | — | — | Endometrial Endometrioid Adenocarcinoma,Malignant Endometrial Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05855811Phase 2 · recruiting PREventing Second Cancers With DOSTARlimab · 89 trials list this drug (59 active) | — | — | Malignant Neoplasm,Primary Malignant Neoplasm,Second Primary Malignant Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05060432Phase 1/Phase 2 · unknown Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors · 89 trials list this drug (59 active) | — | — | Malignant Neoplasm,Malignant Head and Neck Neoplasm,Melanoma+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03250832Phase 1 · completed Study of TSR-033 With an Anti-programmed Cell Death-1 Receptor (PD-1) in Participants With Advanced Solid Tumors · 89 trials list this drug (59 active) | — | — | Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05728814unknown DOstarlimab in Patients With Recurrent or dMMR/MSI-H Endometrial Cancer · 89 trials list this drug (59 active) | — | — | Malignant Endometrial Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04274023Phase 2 · terminated Study on TSR-042 in Advanced Clear Cell Sarcoma · 89 trials list this drug (59 active) | — | — | Clear Cell Sarcoma of Soft Tissue | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05065021Phase 2 · unknown Using Genetic Profile to Determine the Treatment for Patients With Ovarian Cancer Who Previously Received a PARP-inhibitor · 89 trials list this drug (59 active) | — | — | Malignant Fallopian Tube Neoplasm,Malignant Ovarian Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05751629Phase 2 · completed Study to Evaluate the Safety and Efficacy of TSR-042, Bevacizumab, and Niraparib in Participants With Recurrent Ovarian Cancer · 89 trials list this drug (59 active) | — | — | Ovarian Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05405192Phase 2 · withdrawn Dostarlimab in Chemoresistant Gestational Trophoblastic Neoplasia · 89 trials list this drug (59 active) | — | — | Gestational Trophoblastic Tumor | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03955471Phase 2 · terminated Study to Evaluate the Efficacy and Safety of the Combination of Niraparib and Dostarlimab (TSR-042) in Participants With Platinum Resistant Ovarian Cancer · 89 trials list this drug (59 active) | — | — | Ovarian Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04895046Phase 2 · withdrawn Maintenance Niraparib and Dostarlimab in Advanced Cholangiocarcinoma · 89 trials list this drug (59 active) | — | — | Malignant Neoplasm,Cholangiocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04679064Phase 3 · unknown Trial on NIraparib-TSR-042 (Dostarlimab) vs Physician's Choice CHEmotherapy in Recurrent, Ovarian, Fallopian Tube or Primary Peritoneal Cancer Patients Not Candidate for Platinum Retreatment · 89 trials list this drug (59 active) | — | — | Malignant Ovarian Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03806049Phase 3 · withdrawn Trial Comparing Niraparib-bevacizumab-Dostarlimab and Niraparib-bevacizumab to Standard of Care in Recurrent Ovarian Cancer · 89 trials list this drug (59 active) | — | — | Malignant Ovarian Neoplasm | 1 | Observed | clinicaltrials | graph → |